Current status of tamoxifen use: An update for the surgical oncologist. Review uri icon

Overview

abstract

  • The surgical oncologist is frequently responsible for the screening and diagnosis of women with breast cancer. In this pivotal role, they are often the first to discuss treatment options, including nonsurgical interventions, with breast cancer patients. Recent long-term clinical trial data provide support for the use of tamoxifen to prevent breast cancer in women at high risk of the disease. A breast cancer risk assessment can help identify women at higher than average risk for the disease, who may be appropriate candidates for chemoprevention. It is important for the surgical oncologist to understand the current indications and evidence regarding the use of tamoxifen for breast cancer prevention and treatment as they counsel their patients on available options.

publication date

  • September 1, 1999

Research

keywords

  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Estrogen Antagonists
  • Tamoxifen

Identity

Scopus Document Identifier

  • 0032834009

Digital Object Identifier (DOI)

  • 10.1002/(sici)1096-9098(199909)72:1<42::aid-jso13>3.0.co;2-e

PubMed ID

  • 10477879

Additional Document Info

volume

  • 72

issue

  • 1